vidual patients, staging should direct the choice of ther apy and predict its success. In clinical studies, stage grouping should enable comparison of patient popula tions with the same tumor with respect to the results of different treatment modalities. The most widely used TNM classification for oropharyngeal carcinoma and stage grouping, the latter being common for all head and neck carcinomas, is shown in Table l . 1 In oropharyngeal carcinoma, at least 70% of pa tients present with advanced disease (Stages III-IV); more than half of the patients present with Stage IV disease.2-5 Due to the low incidence of this tumor (0.3-0.5% of all malignancies),4,6 few patients have Stages I-II at all. Stages III and IV, on the contrary, are large but heterogeneous. A more balanced distribution over the stages, leading to relative enlargement of Stages I and II and increased coherence of Stages III and, particularly, IV, might add practical value to the current stage group ing. Ideally, this should be obtained through redefining of each stage with respect to T, N, and M, which by themselves remain unchanged. Moreover, the stage grouping should have a stronger prognostic significance than the separate categories included.
In the frame of the nationwide study on oropha ryngeal carcinoma in the Netherlands from 1986 until 1990 conducted by the Dutch Head and Neck Oncology Cooperative Group, data related to epidemiology, treat ment, and survival of 640 patients were collected/ Cur rent staging for this large patient population was criti cally assessed and revised.
M aterials and M ethods
The study was conducted in seven leading centers that participate in the Dutch Head and Neck Oncology Co 
Patients
Six hundred forty patients who were admitted for pri mary treatment of histologically proven squamous cell carcinoma or undifferentiated carcinoma of the oro pharynx were analyzed. Four hundred forty-one pa tients (69%) were males and 199 (31%) females, with a median age of 59 years (range, 30-92 years).
Staging
Staging was done according to the 1992 rules of the In ternational Union Against Cancer (UICC) ,1 which are in accordance with those of the American Joint Com mittee on Cancer (AJCC), as proposed in 19888 (Table  1) . Distribution by T and N is shown in Table 2 . Distant metastases were present in 9 patients (1%), absent in 602 patients (94%), and unknown in 29 patients (5%). Distribution by stage according to the UICC 1992 clas sification, shown in Figure 1 , was as follows: 44 patients (7%), Stage I; 106 (17%), Stage II; 157 (24%), Stage III; 319 (50%), Stage IV, and 14 (2%), unknow n stage.
Vital Status and Survival
At the end of the follow-up, 225 patients (35%) were alive with no evidence of disease (NED), 17 (3%) were alive with tumor, 74 (12%) were dead with NED, 316 (49%) were dead with tumor, and 8 (1%) were lost to follow-up. In surviving patients, median follow-up was at 3 and 6 years, and maximal follow-up was at 7 years. When split up by center, tumor status at death appeared to range from 7-27% of patients having NED, but these differences were likely to have been caused by chance (P = 0.35).
Definitions and Statistical Analysis
Patients were followed up for at least 3 years or until death. Survival was defined as the time between the (2) date of diagnosis and the end of follow-up or death. For the disease specific survival, only those patients who of prognostic factors)/ these dummy variables were added to the model, until no one had a P value of the Results died of oropharyngeal tumor (local, regional, and/or size indicated/ thereby recombining the T, N, and M distant) were considered dead. Survival curves were categories into a new staging, calculated using the life-table method.
Univariate analyses were performed with the log rank statistic. Cox's proportional hazards model was used for multivariate analyses. In the main analysis of stage, we controlled for all variables, as listed in Table 3 .
These data were available for 594 patients* Treat ment modality was used to define strata, and all other variables were used as covariates. To find an optimal combination of T, N, and M categories, we created dummy variables (0 or 1) indicating whether a patient had a T (or N) category larger than a particular value and also all possible products of these dummy variables for T, N, and M resulting in a total of 4X6X2 -1 = 47 dummy variables. However, because not all possible combinations of T, N, and M existed, four had to be deleted. Then, in a stepwise manner (with P values of 0.15 to enter and remove, as standardly used in analysis Revised Staging
The overall survival at 5 years was 28%. The 5-year disease specific survival was 41%; 35% in males and 51% in females (P = 0.003); in soft palate/uvula, 54%; tonsillar region, 42%; base of the tongue, 33%; and in posterior oropharyngeal wall, 32% (P = 0.003); Stage I (UICC, 1992), 6 8 %; II, 64%; III, 44%; and IV, 27% (P < 0.0001) (Fig. 2) ; treatment by surgery alone, 80%; surgery and radiotherapy, 51%; radiotherapy alone, 36%; other treatments, 7%; and no treatment, 5% (P < 0.0001); 5 -year disease specific survival ranged over the centers from 24% to 64% (P == 0.009). Controlled for the variables listed in Table 2 , stage grouping was still associated with survival (P < 0.0001). How ever, when additionally controlled for stage grouping, there is still some evidence that T category (test for linear In [hazard]; P = 0.028) as well as N category (P = 0.031) carry additional prognostic information. In the stepwise procedure, which is used to find an optimal combination of T, N, and M categories, we chose to include M category (P = 0.035) regardless of its P value. Next, T3-4N1-3 (P < 0.0001), N3 (P = 0.0002), Nl-3 (P = 0.032), T3-4 (P = 0.015), and T4N1-3 (P = 0.077) were included consecutively. Finally, T3-4N1-3 (P = 0.36) was again removed.
At this stage, T4N3 had a P value of 0.031, and T2-4N3 had a P value of 0.13, but both had a negative log (relative hazard), indicating that the associated disease specific survival was better than expected on the basis Table 3 . Table 4 . 
Effects of the Revised Staging on Patient Distribution and Disease Specific Survival
crease was observed (P = 0.051). However, a much more impressive change emerged after controlling for the revised staging (P = 0.08) and midline origin in ad dition (P = 0.17).
Apart from stage, for midline origin (P < 0.0001) and sex (P < 0.02), there was persistent evidence for prognostic significance throughout all analyses. For age, this was only the case without controlling for treatment When applied to our patient population, the revised modalities (P -0. The advantages of a more balanced distribution of panoteworthy that revised Stage IV contains only 14% of tients over the stages are obvious: the larger the group, patients (Fig. 3) . A higher proportion of patients with unknown stage in the revised system is caused by the fact that less patients with unknow n M categories could be assigned to Stage IV on the basis of T and N catego ries alone. the more powerful the statistical analyses based on that group can be. As stated in the introduction, the function of staging in directing the choice of therapy may gain practical value with increased Stages I and II, being the favorable groups, and decreasing Stages III and IV into Figure 4 shows the disease specific survival of the the really unfavorable cases. This seems to be of great revised stages, which is superior in prognostic discrimi nation to the UICC 1992 system (Fig. 2) in the case of this sample. The 5-year results with the revised system were 67% in Stage I, 42% in Stage II, 28% in Stage III, and 11% in Stage IV (P < 0.0001). With the revised stag ing, a more pronounced difference between Stages I and II (25% vs. 4% in UICC 1992) seems to have been achieved, so that a small group of patients with an ex tremely poor prognosis corresponding to Stage IV might have been identified. 
Revised Staging and Other Prognostic Factors
Univariately, there was strong evidence of a different prognosis between the centers (P = 0,009), After con trolling for sex, age, and stage UICC 1992, the differ ence decreased to some extent (P = 0.015); when con trolling additionally for midline origin, a further de- 15 like our series, which was also specifically applied to oropharyngeal cancer, is comparable to that of the UICC and the one proposed importance, because in many clinical trials (e.g., organ
UICC TANIS
here because, it includes the M category and results in preservation studies9), all Stage III and IV patients are four stages. When applied to our patient population, the considered eligible candidates, and with the present staging system, this leads to heterogeneous groups of favorable and unfavorable patients. Stage IV, espe cially, should encompass only those patients with a poor prognosis. In our study, increased discrimination between revised stages suggests that such an improve ment may have been obtained. However, it should be noted that our regrouping is optimized for the sample studied here. Therefore, it is to be expected that an ap plication of this revised system to another group of pa tients would result in less diverging curves than shown in Figure 4 . A study to get an independent evaluation of our stage system would be worthwhile, However, the fact that the original stage grouping can be improved on does not follow so much from a comparison of Figure 2 and Figure 4 , but from our finding that T and N catego ries as such carry prognostic information in addition to that of the UICC 1992 stage grouping.
Classification and staging systems in head and neck cancer are regularly evaluated and are being proposed for revisions.1,10"16 Globally, two types of revisions can be distinguished: those affecting definitions of T, N, and/or M that may require changes in diagnostic pro cedures and clinical routine handlings, thus complex in practical implementation, and those limited to regroup ing the existing categories, thereby affecting only ad ministrative aspects of staging. In the update of the TNM classification by UICC in 1987, new definitions of the N category were introduced. 16 The latest update from 1992,1 commented on in 1993,17 did not involve oropharyngeal carcinoma. Stage grouping for head and neck carcinomas, however, has remained unchanged Figure 5 shows diagrammatically the different stage groupings discussed here. Both the TANIS and the Berg systems improve on the stage grouping of the UICC in our material with re spect to prognostic power. The TANIS classification seems to be comparable in this respect with the re grouping proposed here, whereas there is some indica tion that Berg's staging is still somewhat inferior. With respect to the distribution of patients over stages, both are better than the UICC staging, but, as can be seen from the figures given above, are less balanced com pared with the regrouping proposed here. However, a more formal comparison between the four stage group ing systems, performed on independent material, would provide a better evaluation of these systems.
From our study, one can conclude that it is possible to improve the stage grouping of the UICC, leading to a more balanced distribution of patients over the stages and to better discrimination of distinct prognostic groups. Because there is ample evidence that the latest redefinitions of the T and N categories in the UICC and the AJCC classification systems have been real im provements, a comparable refinement of the stage grouping is long overdue.
